anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During pulpotomy treatment, a blood sample was taken from the coronal pulp and stored. The remaining pulp tissue was covered with NeoMTA, randomly selected from among four material groups. The teeth treated with NeoMTA were monitored for 12 months. Subsequently, the levels of IL-6, IL-8, and Presepsin in the blood were measured using the ELISA method and noted in ng/ml. Thus, the effect of the material used on the success of the treatment was determined based on the level of pulpal inflammation before treatment.
There is currently a growing interest in the use of nutraceuticals as a means of preventing the development of complex diseases. Given the considerable health potential of milk-derived peptides, the aim of this study was to investigate the protective effects of glycomacropeptide (GMP) on metabolic syndrome. Particular emphasis was placed on the potential mechanisms mitigating cardiometabolic disorders in high-fat, high-fructose diet-fed mice in the presence of GMP or Bipro, an isocaloric control. The administration of GMP for 12 weeks reduced obesity, hyperglycemia and hyperinsulinemia caused by a high-fat, high-fructose diet, resulting in a decline in insulin resistance. GMP also lessened systemic inflammation, as indicated by decreased circulating inflammatory cytokines. In the intestinal and hepatic tissues, GMP improved homeostasis by increasing insulin sensitivity and attenuating high-fat, high-fructose-induced inflammation, oxidative stress and endoplasmic reticulum stress. Biochemical and histological analyses revealed improved hepatic steatosis and fatty acid composition in the livers of high-fat, high-fructose diet-fed mice treated with GMP compared to Bipro. A trend toward a decrease in bile acids without any marked changes in intestinal microbiota composition characterized GMP-treated animals compared to those administered Bipro. GMP offers considerable potential for fighting metabolic syndrome-related components and complications given its beneficial effects on risk factors such as inflammation, oxidative stress and endoplasmic reticulum stress without involving the intestinal microbiota.
INTRODUCTION: Long working hours are likely associated with the decreased of kidney function, while physical activity (PA) was linked to improvements in kidney function. However, whether PA can offset the negative impact of long working hours on kidney function was unclear, which is the focus of this study.
METHODS: A cross-sectional study was conducted. Three approaches were adopted to distinguish the association between long working hours and regular working hours. Moderate to vigorous physical activity (PA) was assessed by a structured questionnaire. eGFR and chronic kidney disease (CKD) or not were utilized to evaluate the kidney function. Linear and logistic regression analyses were conducted to assess the association between weekly working hours, PA, and kidney function.
RESULTS: A total of 18,431 adults were enrolled in this study, including 9981 males (54.2%) and 8450 females (45.8%). The average eGFR was (99.54 ± 17.55 mL/min/1.73 m2). The people worked more than 40 h/wk (98.89 ± 17.06 mL/min/1.73 m2) had lower eGFR compared to those worked less than 40 h/wk (99.93 ± 17.83 mL/min/1.73 m2) (p < 0.05). Individuals working longer hours exhibited lower eGFR (β = -0.772, 95% CI: -1.241, -0.303, for > 40 h/wk compared to working ≤ 40 h/wk). Engagement in moderate to vigorous PA was associated with higher eGFR values (β = 1.159, 95% CI: 0.699, 1.619) compared to low PA (< 150 minutes/wk), but this association did not reach statistical significance for the prevalence of CKD. Furthermore, PA was insufficient to reverse the decline of eGFR related to prolonged working hours.
DISCUSSION: Prolonged working hours were associated with a decline in eGFR, while PA was found to have a protective effect on kidney function. However, PA alone may not fully mitigate the negative impact of prolonged working hours on renal health. More robust measures to protect renal function should be implemented to mitigate the damage caused by prolonged working hours.
Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
Integrin binding to bioengineered hydrogel scaffolds is essential for tissue regrowth and regeneration, yet not all integrin binding can lead to tissue repair. Here we show that through engineering hydrogel materials to promote α3/α5β1 integrin binding, we can promote the formation of a space filling and mature vasculature compared to hydrogel materials that promote a αvβ3 integrin binding (e.g. RGD). In vivo, α3/α5β1 scaffolds delivering vascular endothelial growth factor (VEGF) promoted non-tortuous blood vessel infiltration and non-leaky blood vessels by 10 days post stroke. In contrast, materials that promote αvβ3 integrin binding promoted endothelial sprout clumping in vitro and leaky vessels in vivo. This work shows for the first time that precisely controlled integrin activation from a biomaterial can be harnessed to direct therapeutic vessel regeneration and reduce VEGF induced vascular permeability in vivo.
Systems and methods for automatic processing of input medical images are provided. A set of input medical images acquired at a plurality of locations on a patient is received. For each respective location of the plurality of locations, an image quality score is determined for each input medical image of the set of input medical images acquired at the respective location and one of the input medical images acquired at the respective location is selected based on the image quality scores. The selected input medical images are processed to correct for errors. One or more regions of interest are segmented from the processed selected input medical images. One or more hemodynamic measures are calculated from the processed selected input medical images based on the segmented one or more regions of interest. The calculated one or more hemodynamic measures are output.
<P>PROBLEM TO BE SOLVED: To provide a method for removing keratotic plugs excellent in removing potential of the keratotic plugs from the skin, namely to provide a method for using a cosmetic sheet for removing keratotic plugs effectively manifesting potentials of the keratotic plug removal.  <P>SOLUTION: The invention relates to the method for using the cosmetic sheet for removing keratotic plugs comprising application of a cosmetic liquid containing polyoxyethylene sorbitan fatty acid ester to the skin before applying the cosmetic sheet for removing keratotic plugs. The keratotic plugs are effectively removed from the skin by using the method. The cosmetic liquid is wiped off or washed and wiped in applying the cosmetic sheet or the sheet is applied on the skin coated with the cosmetic liquid. The cosmetic sheet is removed in a common method.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Cardiovascular disease (CVD) is the leading cause of death of women in the United States, accounting for around 1 of every 3 deaths. Estrogen deficiency, as seen in aging women or after oophorectomy, has been linked to loss of cardiovascular protection, typically seen during reproductive life. Up to half of women evaluated for myocardial ischemia have normal appearing coronary arteries. These women can develop heart failure with a preserved ejection fraction (termed HFpEF) for which the etiology is unclear. Hormonal replacement therapy (HRT) after menopause remains controversial but current evidence cannot support this for either primary or secondary prevention of CVD. There are clearly modulatory influences on estrogenic signaling, that could well influence cardiovascular health in later life. Previous studies have demonstrated that estrogen improves energy production within the heart by increasing 5' adenosine monophosphate-activated protein (AMPK) and mitochondrial biogenesis via upregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α); a master switch of mitochondrial function, linked to vascular integrity and angiogenesis. Estrogen has been also found to modulate purinergic signaling by boosting expression of adenosine receptors and of CD39, the dominant endothelial ecto-ADPase that generates adenosine. There are also close relationships between purinergic signaling and dipeptidyl peptidase-4 (DPP-4; otherwise known as adenosine deaminase complexing protein 2 or CD26), possibly mediated by adenosine deaminase bioactivity. Decreased PGC-1α and aberrant purinergic signaling in metabolic syndrome may lead to impaired mitochondrial function, provoking diastolic dysfunction, and also result in impaired angiogenesis. The investigators hypothesize there are central roles of PGC-1α, purines and DPP-4 linked neuropeptide pathways in the control of angiogenesis and mitochondrial activity. These become increasingly disordered in setting of estrogen loss provoking development of metabolic syndrome, thereby exacerbating HFpEF and microvascular disease. Specific Aim 1: To determine how ischemia and cardiometabolic dysfunction in women's heart disease are exacerbated by the loss of puringeric pathways from estrogen deficiency. The investigators expect to determine that diastolic dysfunction is a functional consequence of this microvascular loss and cardiometabolic dessynchrony. Specific Aim 2: To evaluate the role of adenosingergic receptor activation and DPPIV inhibition on angiogenesis in a ovariectomized swine model of chronic myocardial ischemia and metabolic syndrome. Here, the investigators will explore relationships between the regulated and linkages in the exocytosis of nucleotides and neuropeptides, formation of nucleosides (adenosine) and alterations in angiogenic activity secondary to these. Summary: The investigators will study fundamental mechanisms in heart disease underpinning biological differences in women. The investigators will also offer new therapeutic strategies that target cardiac metabolism.
Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
Aspects of the present invention relate inter alia to compositions which may have utility as anti-microbials. Such antimicrobial compositions may be for use in promoting wound healing and/or the treatment of microbial infections. In certain embodiments, the invention relates to an antimicrobial composition and/or combinations comprising copper gluconate and zinc gluconate which may be for use in treating and/or preventing infections and/or promoting wound healing. Certain aspects of the present invention further relate to an antimicrobial composition and/or device comprising copper gluconate, zinc gluconate and Lactobacillus plantarum for use in treating infections and/or promoting wound healing. Also encompassed by the present invention are methods of treating microbial and/or fungal infections in a subject, for example infections of the genital tract. Aspects of the present invention include a composition comprising a zinc salt and a copper salt, wherein the zinc salt is zinc gluconate and the copper salt is copper gluconate.
Implantable systems, and methods for use therewith, monitor a patient's arterial blood pressure without requiring an intravascular pressure transducer. A plurality of calibrations factors are stored, each of which is associated with a respective one of a plurality of different postures, activity levels, or HR ranges, or different combinations thereof. A signal indicative of activity of the patient's heart, and a signal indicative of changes in arterial blood volume of the patient are obtained, and a pulse arrival time (PAT) value is determined. A current posture, activity level, and/or HR of the patient is/are determined and used to identify stored calibration factor(s) that correspond thereto. Values indicative of the patient's arterial blood pressure is/are determined based on the PAT value and the stored calibration factor(s) identified based on the patient's current posture, activity level, and/or HR. Such value(s) and/or changes thereto can be used to trigger and/or adjust therapy.
A shampoo composition comprises (a) an aqueous solution of an anionic detergent having dissolved therein (b) one or more nitroamino dyes of formula <FORM:0889327/III/1> wherein n is 1 or 2, and (c) a fatty acid alkanolamide which is present in an amount which substantially increases the apparent solubility of the dye.  Anionic detergents referred to are sodium dodecylbenzene sulphonate, sec-alkyl or lauryl sulphate, or dioctyl sulphosuccinate; triethanolamine oleate; or mono- or tri-ethanolamine lauryl sulphate.  The dye suitably comprises 0,5-2% by weight of the composition and is preferably 4-nitro-1:2-diaminobenzene, 2-nitro-1:4-diaminobenzene, or 2-amino-4:6-dinitrophenol.  The alkanolamide is suitably the diethanolamide or mono-isopropanolamide of lauric or coconut fatty acid, and is usually present in an amount of 2-25% by weight of the composition.  Glycol monostearate and cetyl alcohol may also be incorporated.  Specification 707,618 is referred to.ALSO:Hair may be tinted by the use of a shampoo composition comprising an aqueous solution of (a) an anionic detergent having dissolved therein, (b) one or more nitroamino dyes of formula <FORM:0889327/IV (c)/1> wherein n is 1 or 2, and (c) a fatty acid alkanolamide which is present in an amount which substantially increases the apparent solubility of the dye.  Anionic detergents referred to are sodium dodecylbenzene sulphonate, sec-alkyl or lauryl sulphate, or dioctyl sulphosuccinate, triethanolamine oleate, or mono- or tri-ethanolamine lauryl sulphate.  The dye suitably comprises 0.5%-2% by weight of the composition and is preferably 4-nitro-1 : 2-diaminobenzene, 2-nitro-1 : 4-diaminobenzene, or 2-amino-4 : 6-dinitrophenol.  The alkanolamide is suitably the diethanolamide or monoisopropanolamide of lauric or coconut fatty acid, and is usually present in an amount of 2%-25% by weight of the composition.  Glycol monostearate and cetyl alcohol may also be incorporated.  Specification 707,618 is referred to.
College aged students tend to report significant daily stress but there is no research on herbal interventions to ameliorate this condition in this population.

This study is a mixed methods, randomized, double blinded, placebo controlled 30 day trial targeting a college aged population. Participants are randomly allocated to either an intervention group (ashwagandha) or a placebo group. Each participant is given a bottle of capsules (capsules look identical but are filled either with a full spectrum dried extract ashwagandha herb or a placebo filled with glycerin). Directions included consuming 1 capsule in the morning and one capsule in the evening. Questionnaires were collected prior to the study and at the end of the study, including an assessment of daily affect. A subset of each group volunteered to attend an intervention specific focus group at 30 days completion of the study.
Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the "LBC arm." Screening performed 2.5 yearly.
Eligible patients randomized to this arm will receive Atorvastatin 80mg as monotherapy for LDL-C reduction. They can be upgraded to combination (adding Ezetimibe 10mg) if found in follow-up that they had not achieve recommended LDL-C targets.
Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
The present invention discloses a lysin that is capable of killing  Staphylococcus  and the use thereof, belonging to the field of biological agents. The present invention discloses the amino acid sequence and the encoding gene sequence of the lysin. This lysin keeps active in a wide range of pH. It has lytic activity against  Staphylococcus  in pH 4-11. The recombinant protease constructed by the encoding gene can be solubly expressed in  E.coli  strain BL21 (DE3). The lysin can be used to effectively kill multiple species  Staphylococcus in vitro,  including methicillin sensitive  Staphylococcus aureus  (MSSA) and methicillin resistant  Staphylococcus aureus  (MRSA) isolated in clinics. This lysin can be used as an antibiotic for the treatment of staphylococcal infections  in vivo.  This lysin is also able to rapidly lyse staphylococcal cell wall; as a result, intracellular substances such as ATP and DNA are released. Those released substances can be used to detect the type of  Staphylococcus.
The invention provides a novel acne treatment powder with a good acne treatment effect and without toxic or side effect and a preparation method thereof. The novel acne treatment powder is prepared from the following raw materials in percentage by weight: 10-20% of each of iphigenia indica, philippine violet herb, spreading hedyotis herb and rumex madaio leaf, and 5-8% of each of rhubarb, baikal skullcap root, cortex phellodendri, sulfur and mung beans. The preparation method comprises the following steps: crushing the raw materials into powder respectively, uniformly and fully mixing all the powder, and packaging with 50g a bag by using packaging bags. The using method of the novel acne treatment powder comprises the following steps: taking 1 bag of the powder every time, uniformly blending the powder, and then externally applying the powder to affected parts. In the patent, the iphigenia indica has functions of reducing swelling, removing stasis and detoxifying, the philippine violet herb and the spreading hedyotis herb have functions of clearing heat, promoting diuresis, detoxifying and reducing swelling, the rhubarb, baikal skullcap root and cortex phellodendri have a function of clearing heat-fire, the sulfur is externally used for detoxifying, destroying parasites and softening scarfskin, the mung beans has functions of clearing heat and detoxifying, and the rumex madaio leaf has functions of clearing heat and expelling wind. The novel acne treatment powder has an extremely good acne treatment effect.
The invention discloses a kaurane type diterpenoid compound for treating prostatic cancer, and provides a compound structure, a medicine composition containing the compound, and a preparation method and application of the compound. The compound is reported for the first time, and belongs to the kaurane type diterpenoid compound with a novel structure. The compound can be obtained through extraction, separation and purification from dried fructus alpiniae oxyphyllae. In-vitro tests prove that the compound has an inhibition effect on prostatic cancer cell strains PC3 and DU145. In addition, the inhibiting effect has the concentration-time dependency relationship. The compound can be used for being developed into medicine for treating the prostatic cancer.
Respiratory distress (RD) has been reported in SARS-CoV-2 exposed uninfected (SEU) term neonates. Prior studies suggest that prenatal exposure to Coronavirus Disease 19 (COVID-19) may activate an inflammatory cascade in the newborn airway. In this study, we examine the relationship between maternal COVID-19 vaccination and neonatal RD using a longitudinal cohort of mother-infant pairs in Los Angeles, CA. Two-hundred and twenty-one mothers with laboratory confirmed SARS-CoV-2 during pregnancy and 227 exposed fetuses are enrolled in our study. Maternal disease severity and neonatal RD variables were defined based on current accepted clinical criteria. To explore the multifactorial associations between maternal COVID-19 parameters and infant RD, we utilize a multivariable logistic regression model and a proteomic sub-analysis to propose a pathway for the development of RD following in utero exposure to SARS-CoV-2. Unusually high rates of RD are observed in SEU infants (17%). The odds ratio of RD is 3.06 (95% CI:1.08-10.21) in term neonates born to unvaccinated individuals versus those born to individuals vaccinated prior to maternal infection. Proteomic analysis reveals a robust inflammatory response associated with ciliary dysregulation and enhanced IgE production among SEU neonates with RD. Maternal vaccination against COVID-19 reduces the frequency of neonatal RD.
Allocation of treatment intensity by the proposed AI algorithm will be based on the machine learning and natural language processing (NLP) of textual data provided by participants and their PHQ-9 score collected through a pre-treatment screening module called the Triage Module. This module, developed by the research team, (1) provides psychoeducation on the effects of psychotherapy, (2) collects PHQ-9 scores, and (3) asks participants six open-ended questions regarding their mental health history, their experiences with mental health disorders, and what mental health difficulties they are currently facing. Based on the participant's answers to the open-ended questions, a variable called "Symptomatic Score" will be calculated using the NLP algorithm.
BACKGROUND: Cycloheximide (CXM), an antifungal antibiotic, causes impaired memory consolidation as a side effect partially by disturbing the activities of the central catecholaminergic and cholinergic system. Some reports indicated that puerarin prevented memory impairment in various models in rodents. However, the protective effects of puerarin on the side effects of cycloheximide for memory consolidation impairment have not yet been investigated.
METHODS: The protective effects of puerarin on CXM-induced memory-consolidation impairment, and memory impairment produced by central administration of AF64A neurotoxin, were investigated using a passive avoidance task in rats. A combination of transmitter receptor agonists and antagonists was used to explore the effects of puerarin on nervous system function. The activity of antioxidant defense systems and neurotransmitter systems in the prefrontal cortex and hippocampus were assayed.
RESULTS: Systemic (25 and 50 mg/kg, i.p.) or central (5 and 10 µg/brain, i.c.v.) administration of puerarin attenuated CXM-induced memory-consolidation impairment produced by 1.5 mg/kg CXM (s.c.) in rats. The improvements produced by 50 mg/kg puerarin were blocked by cholinergic antagonists, a 5-HT2 receptor agonist, and an adrenergic receptor antagonist. Puerarin (only at 50 mg/kg, i.p.) reversed the CXM-induced alterations of the levels of norepinephrine in the prefrontal cortex and the levels of monoamines in the hippocampus. Puerarin also increased antioxidant-defense-system activities in the prefrontal cortex and hippocampus, which had been decreased by CXM.
CONCLUSIONS: We suggested that the attenuating effects of puerarin on CXM-induced memory-consolidation impairment may be due to decrease oxidative damage and the normalition of the neurotransmitter function in the prefrontal cortex and hippocampus.